Development and characterization of DIA 12.3, a fully human intact anti-CEACAM1 monoclonal antibody

Development and characterization of DIA 12.3, a fully human intact anti-CEACAM1 monoclonal antibody

Show other versions (1)

Bibliographic Details
Main Authors:	Michela Centonze, Valentina Fiori, Maciej Kujawski, Lin Li, Patty Wong, Lindsay Williams, Tomas Di Mambro, Sabrina Dominici, Angelo Sparti, John E. Shively, Mauro Magnani
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861082/?tool=EBI

Similar Items

Development and characterization of DIA 12.3, a fully human intact anti-CEACAM1 monoclonal antibody.
by: Michela Centonze, et al.
Published: (2024-01-01)

Role of CEACAM1 and CEACAM20 in an in vitro model of prostate morphogenesis.
by: Hui Zhang, et al.
Published: (2013-01-01)

CEACAM expression in an in-vitro prostatitis model
by: Irina Kube-Golovin, et al.
Published: (2023-08-01)

Interactions of pathogenic Escherichia coli with CEACAMs
by: Alaullah Sheikh, et al.
Published: (2023-02-01)

CEACAM1 expression in pancreatic endocrine tumors.
by: Serra, S, et al.
Published: (2009)

Structural analysis of human CEACAM1 oligomerization
by: Amit K. Gandhi, et al.
Published: (2022-09-01)

Phenotypic screen of sixty-eight colorectal cancer cell lines identifies CEACAM6 and CEACAM5 as markers of acid-resistance
by: Michl, J, et al.
Published: (2024)

Controling the cytoskeleton during CEACAM3-mediated phagocytosis
by: Johannes W.P. Kuiper, et al.
Published: (2024-03-01)

Antiplatelet effects of the CEACAM1-derived peptide QDTT
by: Yujia Ye, et al.
Published: (2024-12-01)

CEACAM1 recognition by bacterial pathogens is species-specific
by: Kammerer Robert, et al.
Published: (2010-04-01)

Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy
by: Arthur Hinterholzer, et al.
Published: (2022-12-01)

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
by: Anja Seckinger, et al.
Published: (2023-12-01)

Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria.
by: Sadarangani, M, et al.
Published: (2011)

Opa proteins and CEACAMs: Pathways of immune engagement for pathogenic Neisseria
by: Sadarangani, M, et al.
Published: (2011)

Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria
by: Sadarangani, M, et al.
Published: (2011)

CEACAM7 expression contributes to early events of pancreatic cancer
by: Anupam Dhasmana, et al.
Published: (2024-01-01)

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
by: Huang, Yu-Hwa, et al.
Published: (2015)

Extending the capabilities of intact-mass analyses to monoclonal immunoglobulins of the E-isotype (IgE)
by: Wenhua Yang, et al.
Published: (2022-12-01)

CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA
by: Benediktas Kurlinkus, et al.
Published: (2021-06-01)

Comparison of IL‐2‐antibody to IL‐2‐Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors
by: Lindsay Williams, et al.
Published: (2024-02-01)

Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease
by: Callaghan, M, et al.
Published: (2008)

Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease.
by: Callaghan, M, et al.
Published: (2008)

Age-related degradation of tectorial membrane dynamics with loss of CEACAM16
by: Mansour, Amer, et al.
Published: (2022)

Investigations on the Usefulness of CEACAMs as Potential Imaging Targets for Molecular Imaging Purposes
by: Heine, Markus, et al.
Published: (2012)

CEACAM6 serves as a biomarker for leptomeningeal metastasis in lung adenocarcinoma
by: Xueying Wang, et al.
Published: (2023-02-01)

CEACAM1-4L promotes anchorage-independent growth in melanoma
by: Stefanie eLoeffek, et al.
Published: (2015-10-01)

A fully automated FAIMS-DIA mass spectrometry-based proteomic pipeline
by: Luke Reilly, et al.
Published: (2023-10-01)

MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma
by: Seung-Myoung Son, et al.
Published: (2023-09-01)

Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
by: Jinhu Li, et al.
Published: (2023-03-01)

An investigation into the role of inherited CEACAM gene family variants and colorectal cancer risk
by: Anna L. W. Huskey, et al.
Published: (2022-02-01)

Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
by: Miguel Burgos, et al.
Published: (2022-01-01)

Increased CEACAM1 expression on peripheral blood neutrophils in patients with rheumatoid arthritis
by: Haruki Matsumoto, et al.
Published: (2022-12-01)

Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients.
by: Markel, G, et al.
Published: (2004)

A Multimode Microfiber Specklegram Biosensor for Measurement of CEACAM5 through AI Diagnosis
by: Yuhui Liu, et al.
Published: (2024-01-01)

Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
by: Haojun Shi, et al.
Published: (2022-12-01)

Effects of Helicobacter pylori adhesin HopQ binding to CEACAM receptors in the human stomach
by: Quynh Anh Nguyen, et al.
Published: (2023-02-01)

Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study )
by: Abla Sayed Mahmoud, et al.
Published: (2021-06-01)

Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B
by: Takuhiro Matsumura, et al.
Published: (2020-05-01)

Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase
by: Kanasap Kaewchim, et al.
Published: (2021-10-01)

Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma
by: Dennis Awuah, et al.
Published: (2023-11-01)